Melane Sampson, Author at BioTuesdays

Developments

MedMira launches clinical trial for Multiplo TP/HIV self-test in Canada

MedMira (TSXV: MIR) has announced the launch of a clinical trial to evaluate its Multiplo TP/HIV rapid test for use as a self-test in Canada. Multiplo is a dual HIV and syphilis rapid self-test that delivers immediate...

July 7, 2025

Developments

Cyclacel highlights publication in Gut showing plogosertib is active in FLC

Cyclacel Pharmaceuticals (NASDAQ: CYCC; NASDAQ: CYCCP) has announced the publication of independent research in the peer-reviewed medical journal Gut demonstrating that plogosertib, a PLK1 inhibitor, is active in...

July 7, 2025

Developments

Cancer Cell highlights preclinical data of Tonix’s mTNX-1700 in gastric cancer models

Tonix Pharmaceuticals (NASDAQ: TNXP) has announced the publication of a paper in the peer-reviewed journal Cancer Cell, presenting data demonstrating that treatment with murine TNX-1700 (mTNX-1700) increased survival...

July 2, 2025

Developments

Clearmind doses first patient in trial of MEAI-based treatment for AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that the first patient has been dosed in its Phase 1/2a clinical trial of its proprietary MEAI-based oral drug candidate, CMND-100, for the treatment of alcohol...

July 2, 2025

Developments

Medical City Dallas Hospital enhances surgical precision with Perimeter’s OCT imaging technology

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that Medical City Dallas Hospital—an award-winning, 899-bed acute care hospital in the Dallas-Fort Worth area—has adopted the company’s current...

July 2, 2025

Feature

Dotmatics empowering life-changing discoveries with next-gen therapeutic research solution

Closely held Dotmatics is transforming the therapeutic research and development landscape with Luma, a groundbreaking solution in multimodal data management with the potential to address long-standing scientific...

July 1, 2025

Developments

Artelo reports positive first-in-human results for novel non-opioid pain therapy

Artelo Biosciences (NASDAQ: ARTL) has announced positive results from its first-in-human study evaluating its novel non-opioid candidate, ART26.12, for the treatment of persistent pain. ART26.12 is the first orally...

June 30, 2025

Developments

KalVista grants Pendopharm rights to commercialize sebetralstat for HAE

KalVista Pharmaceuticals (NASDAQ: KALV) has announced that it has entered into a licensing agreement with closely held Pendopharm to manage the regulatory approval process and commercialization of sebetralstat, an...

June 26, 2025

Developments

NMPA approves Theravance’s YUPELRI for COPD in China

Theravance Biopharma (NASDAQ: TBPH) has announced that China’s National Medical Products Administration (NMPA) has granted regulatory approval for YUPELRI, the company’s revefenacin inhalation solution for the treatment...

June 26, 2025

Developments

Clearmind adds leading Israeli clinical site to ongoing trial of CMND-100 in AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has added Tel Aviv Sourasky Medical Center (TASMC) to the list of clinical sites for its ongoing Phase 1/2a trial evaluating CMND-100—a proprietary MEAI...

June 24, 2025

Author - Melane Sampson

MedMira launches clinical trial for Multiplo TP/HIV self-test in Canada

Cyclacel highlights publication in Gut showing plogosertib is active in FLC

Cancer Cell highlights preclinical data of Tonix’s mTNX-1700 in gastric cancer models

Clearmind doses first patient in trial of MEAI-based treatment for AUD

Medical City Dallas Hospital enhances surgical precision with Perimeter’s OCT imaging technology

Dotmatics empowering life-changing discoveries with next-gen therapeutic research solution

Artelo reports positive first-in-human results for novel non-opioid pain therapy

KalVista grants Pendopharm rights to commercialize sebetralstat for HAE

NMPA approves Theravance’s YUPELRI for COPD in China

Clearmind adds leading Israeli clinical site to ongoing trial of CMND-100 in AUD

Subscribe